贵金属新材料AI
Search documents
贵研铂业:拟向特定对象增发募资不超过12.91亿元
Mei Ri Jing Ji Xin Wen· 2025-09-22 10:18
Group 1 - The core point of the news is that Guiyan Platinum Industry has approved a plan to issue shares to specific investors, aiming to raise up to 1.291 billion yuan for various projects [1] - The share issuance will involve no more than 35 specific investors and will not exceed 30% of the total share capital prior to the issuance, amounting to approximately 228 million shares [1] - The funds raised will be allocated to several projects, including the construction of a key laboratory platform for precious metal functional materials, an AI laboratory for new materials, and various recycling and processing projects [1] Group 2 - For the first half of 2025, the revenue composition of Guiyan Platinum Industry includes 36.21% from precious metal recycling materials, 35.17% from precious metal trading, 16.05% from special functional materials, 8.65% from precursor materials, and 3.01% from automotive catalytic purifiers [2] - As of the latest report, the market capitalization of Guiyan Platinum Industry is 12.3 billion yuan [3]
贵研铂业(600459.SH):拟定增募资不超12.91亿元
Ge Long Hui A P P· 2025-09-22 10:09
Core Viewpoint - Guiyan Platinum Industry (600459.SH) announced a plan to issue A-shares to specific investors, aiming to raise no more than 1.291 billion yuan for various projects [1] Fundraising and Investment Projects - The total amount to be raised from the issuance of A-shares is capped at 1.291 billion yuan, including the principal amount [1] - The raised funds will be allocated to several key projects, including: - Construction of a national key laboratory platform for precious metal functional materials - Establishment of an AI laboratory for new precious metal materials - Development of a modern industrial base for the recycling of secondary precious metal resources - Green recycling project for secondary precious metal resources - Deep processing and intelligent upgrading of new functional alloys - Industrialization of platinum-based anticancer drug raw materials - Supplementing working capital [1]